Overview

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Status:
Completed
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
Phase:
Phase 3
Details
Lead Sponsor:
Relypsa, Inc.
Vifor Pharma, Inc.
Collaborator:
Vifor Pharma